Cancer Care of Central Pennsylvania to join Geisinger Cancer Institute

Danville, Pa.-based Geisinger Cancer Institute and Lewisburg, Pa.-based Cancer Care of Central Pennsylvania have announced an agreement in which Cancer Care of Central Pennsylvania will become party of the Geisinger family, effective Dec. 1.

Advertisement

The agreement between the organizations includes Cancer Care of Central Pennsylvania’s Lewisburg, Selinsgrove, Elysburg and Lock Haven locations. Geisinger will begin renovations at these sites and rename them Geisinger Cancer Center-Lewisburg, Geisinger Medical Oncology-Selinsgrove, Geisinger Medical Oncology-Elysburg and Geisinger Medical Oncology-Lock Haven, respectively.

Geisinger Cancer Center-Lewisburg will include expanded treatment rooms with capabilities for medical oncology services including chemotherapy, IV infusions, injections, hydrations and bone marrow biopsies, as well as radiation oncology care including intensity modulated radiation therapy, image guided radiation therapy, a CT scanner to be used for radiation treatment planning and an on-site pharmacy.

The Elysburg, Lock Haven and Selinsgrove locations will provide IV infusions, injections, hydrations and bone marrow biopsies. Laboratory services will be available in both Elysburg and Selinsgrove.

More articles on hospital and health system transactions:
35 hospital transactions and partnerships in October
CVS Health enters into clinical affiliations with 4 health systems
Cayuga Medical Center, Schuyler Hospital partner to create new health network to create new health network

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Advertisement

Next Up in Transactions & Valuation Issues

Advertisement

Comments are closed.